The Global Panobinostat Market was valued at USD 287.5 Million in 2023 and is projected to reach USD 472.8 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period (2024–2030). This growth is fueled by increasing prevalence of multiple myeloma, rising healthcare expenditures, and expanding applications of HDAC inhibitors in cancer treatment.

As the oncology landscape evolves with novel therapeutic approaches, pharmaceutical companies are racing to develop and commercialize effective panobinostat formulations. In this analysis, we examine the Top 10 Companies in the Panobinostat Market — including innovators, generic manufacturers, and research specialists shaping the future of HDAC inhibitor treatments.

---

🔟 1. Novartis AG

Headquarters: Basel, Switzerland
Key Product: Farydak (panobinostat) capsules

Novartis is the original developer and primary patent holder of panobinostat, marketed as Farydak for relapsed multiple myeloma. The company leads in clinical research and combination therapies involving this HDAC inhibitor.

Recent Developments:

• FDA-approved for combo therapy with bortezomib and dexamethasone

• Ongoing trials for expanded oncology indications

• Strategic partnerships for targeted delivery systems

Download FREE Sample Report:
Panobinostat Market – View in Detailed Research Report

---

9️⃣ 2. Pfizer Inc.

Headquarters: New York, USA
Key Offering: Generic panobinostat under development

Pfizer is positioning itself in the panobinostat pipeline through its established oncology portfolio and generics division, preparing for post-patent market entry with competitive formulations.

Strategic Initiatives:

• Preparation for generic market entry

• Exploring novel formulation technologies

---

8️⃣ 3. Teva Pharmaceutical Industries

Headquarters: Tel Aviv, Israel
Key Offering: Generic oncology portfolio including panobinostat

As one of the world’s largest generic drug manufacturers, Teva is developing cost-effective panobinostat alternatives expected to improve treatment accessibility in emerging markets.

Market Strategy:

• Focus on emerging market penetration

• Developing patient assistance programs for affordability

---

7️⃣ 4. Ambeed

Headquarters: Arlington Heights, USA
Key Offering: High-purity panobinostat for research

Ambeed specializes in supplying high-grade panobinostat for clinical research and drug development purposes, serving pharmaceutical companies and academic institutions globally.

Research Focus:

• GMP-grade HDAC inhibitor compounds

• Custom synthesis services

---

6️⃣ 5. BioVision, Inc.

Headquarters: Milpitas, California
Key Offering: Panobinostat for biochemical research

BioVision provides high-quality panobinostat solutions for preclinical studies and mechanistic research in oncology and epigenetics.

Technical Advantages:

• 99%+ purity standards

• Comprehensive analytical data packages

Download FREE Sample Report:
Panobinostat Market – View in Detailed Research Report

---

5️⃣ 6. APExBIO Technology LLC

Headquarters: Houston, Texas
Key Offering: Panobinostat research compounds

APExBIO supplies panobinostat and related HDAC inhibitors to support drug discovery programs and academic research initiatives worldwide.

Product Portfolio:

• Solution and powder formulations

• Stable isotope-labeled versions

---

4️⃣ 7. Selleck Chemicals

Headquarters: Houston, Texas
Key Offering: Panobinostat for screening libraries

Selleck Chemicals provides panobinostat as part of its extensive collection of pharmacologically active compounds used in high-throughput screening.

Quality Standards:

• QC verified bioactivity

• GMP-like manufacturing

---

3️⃣ 8. MedChemExpress (MCE)

Headquarters: Monmouth Junction, NJ
Key Offering: Panobinostat analytical standards

MCE offers certified reference materials and bioactive compounds for pharmaceutical research and development of HDAC inhibitors.

Technical Services:

• Stability testing

• Method development

---

2️⃣ 9. Cayman Chemical Company

Headquarters: Ann Arbor, Michigan
Key Offering: Research-grade panobinostat

Cayman Chemical provides high-purity panobinostat for academic and industrial research applications with comprehensive characterization data.

Quality Assurance:

• Batch-specific certificates of analysis

• Strict regulatory compliance

Get Full Report Here:
Panobinostat Market – View in Detailed Research Report

---

1️⃣ 10. Toronto Research Chemicals

Headquarters: North York, Canada
Key Offering: Specialty panobinostat derivatives

TRC manufactures and supplies innovative panobinostat analogs and metabolites for advanced research into HDAC inhibitor mechanisms.

Innovation Focus:

• Isotope-labeled forms

• Metabolite standards

---

🔬 Outlook: The Future of Panobinostat in Precision Oncology

The panobinostat market is experiencing significant evolution as researchers uncover new applications and improve delivery mechanisms for this potent HDAC inhibitor.

📈 Key Trends Shaping the Market:

• Expanding clinical applications beyond multiple myeloma

• Development of next-generation HDAC inhibitors with improved safety profiles

• Growing focus on combination therapies with immunotherapies

• Increasing research into epigenetic mechanisms of cancer

Get Full Report Here:
Panobinostat Market – View in Detailed Research Report

The companies profiled above are at the forefront of developing and commercializing panobinostat solutions, driving innovation in epigenetic cancer therapies.